Profil
Dr. David M.
Gravett is Vice President-Research & Development at Carbylan Therapeutics, Inc.
Dr. Gravett was previously employed as Vice President-Formulations & Polymer Chemistry by Angiotech Pharmaceuticals, Inc. and a Principal by Pasteur Mérieux Connaught.
He received his doctorate degree from the University of Toronto.
Anciens postes connus de David M. Gravett
| Sociétés | Poste | Fin |
|---|---|---|
Carbylan Therapeutics, Inc.
 Carbylan Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Carbylan Therapeutics, Inc. engages in the development and market of medical devices and drug combination products to treat the pain associated with osteoarthritis. It offers Hydros Joint Therapy and Hydros-TA Joint Therapy, viscoelastic hyaluronan-based products designed to provide long term relief of the pain associated with osteoarthritis using a single intra-articular injection. The company was founded by Richard R. Orlandi, Albert Park, Glenn D. Prestwich and Richard K. Koehn in March 2004 and is headquartered in Palo Alto, CA. | Directeur Technique/Scientifique/R&D | 15/04/2016 |
Angiotech Pharmaceuticals, Inc.
 Angiotech Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, which engages in developing, manufacturing and marketing medical products and technologies, within the areas of interventional oncology, wound closure and ophthalmology. The company was founded by William L. Hunter and Cruz F. Tony in 1992 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - |
| Pasteur Mérieux Connaught | Corporate Officer/Principal | - |
Formation de David M. Gravett
| University of Toronto | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Angiotech Pharmaceuticals, Inc.
Angiotech Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company, which engages in developing, manufacturing and marketing medical products and technologies, within the areas of interventional oncology, wound closure and ophthalmology. The company was founded by William L. Hunter and Cruz F. Tony in 1992 and is headquartered in Vancouver, Canada. | Health Technology |
| University of Natal | Consumer Services |
Carbylan Therapeutics, Inc.
Carbylan Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Carbylan Therapeutics, Inc. engages in the development and market of medical devices and drug combination products to treat the pain associated with osteoarthritis. It offers Hydros Joint Therapy and Hydros-TA Joint Therapy, viscoelastic hyaluronan-based products designed to provide long term relief of the pain associated with osteoarthritis using a single intra-articular injection. The company was founded by Richard R. Orlandi, Albert Park, Glenn D. Prestwich and Richard K. Koehn in March 2004 and is headquartered in Palo Alto, CA. | Health Technology |
| Pasteur Mérieux Connaught |